Remedium Lifecare Board of Directors

Get the latest insights into the leadership at Remedium Lifecare. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Adarsh Munjal Whole Time Director
Mr. Hanosh Santok Non Executive Director
Ms. Maneesha Naresh Independent Director
Ms. Trupti Bolke Independent Director
Mr. Pratik Shah Independent Director
Ms. Seema Sanei Independent Director

Remedium Lifecare Share price

REMLIFE

1.32

0.04 (3.13%)
Last updated on 4 Sep, 2025 | 15:55 IST
BUYSELL
Today's High

1.33

Today's Low

1.24

52 Week Low

0.80

52 Week High

7.39

The current prices are delayed, login to your account for live prices

Remedium Lifecare FAQs

The board at Remedium Lifecare consists of experienced professionals, including Mr. Adarsh Munjal , Mr. Hanosh Santok , and others, overseeing the company’s strategic and corporate governance.

Directors at Remedium Lifecare are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Adarsh Munjal is the current chairman at Remedium Lifecare.

Executive directors at Remedium Lifecare are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Remedium Lifecare adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Remedium Lifecare, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.